140 related articles for article (PubMed ID: 7479389)
21. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
[TBL] [Abstract][Full Text] [Related]
22. In vivo antitumor activity of bropirimine against PAIII and Dunning MAT-LyLu rodent prostate cancers.
Sarosdy MF; Higdon AL; Demoor CA
J Urol; 1996 Jun; 155(6):2085-9. PubMed ID: 8618341
[TBL] [Abstract][Full Text] [Related]
23. Rat PSP94 inhibits the growth and viability of the rat adenocarcinoma cell line PAIII in vitro.
Cadieux PA; Mikolajczak SA; Reeves J; Strathdee C; Reid G; Panchal CJ; Clarke MW
Cancer Invest; 2006; 24(3):246-55. PubMed ID: 16809150
[TBL] [Abstract][Full Text] [Related]
24. Small intestinal submucosa does not promote PAIII tumor growth in Lobund-Wistar rats.
Hodde JP; Suckow MA; Wolter WR; Hiles MC
J Surg Res; 2004 Aug; 120(2):189-94. PubMed ID: 15234212
[TBL] [Abstract][Full Text] [Related]
25. Effect of dimethylsulfoxide on the proliferation and glycosaminoglycan synthesis of rat prostate adenocarcinoma cells (PAIII) in vitro: isolation and characterization of DMSO-resistant cells.
Kaneski CR; Constantopoulos G; Brady RO
Prostate; 1991; 18(1):47-58. PubMed ID: 1987579
[TBL] [Abstract][Full Text] [Related]
26. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.
Sato M; Turner CH; Wang T; Adrian MD; Rowley E; Bryant HU
J Pharmacol Exp Ther; 1998 Oct; 287(1):1-7. PubMed ID: 9765314
[TBL] [Abstract][Full Text] [Related]
27. Effect of coumarin on the normal rat prostate and on the R-3327H prostatic adenocarcinoma.
Omarbasha B; Fair WR; Heston WD
Cancer Res; 1989 Jun; 49(11):3045-9. PubMed ID: 2720665
[TBL] [Abstract][Full Text] [Related]
28. The selective estrogen receptor modulator, raloxifene: segment II studies in rats and rabbits.
Byrd RA; Francis PC
Reprod Toxicol; 1998; 12(3):261-70. PubMed ID: 9628550
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
Lokeshwar BL; Schwartz GG; Selzer MG; Burnstein KL; Zhuang SH; Block NL; Binderup L
Cancer Epidemiol Biomarkers Prev; 1999 Mar; 8(3):241-8. PubMed ID: 10090302
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms subserving the bipotential actions of estrogen on ovarian cells: studies with a selective anti-estrogen, LY156758, and the sparingly metabolizable estrogen agonist, moxestrol.
Veldhuis JD
J Steroid Biochem; 1986 May; 24(5):977-82. PubMed ID: 3459942
[TBL] [Abstract][Full Text] [Related]
31. Oral bropirimine immunotherapy of rodent prostate cancer.
Sarosdy MF
Eur Urol; 1997; 31 Suppl 1():5-9. PubMed ID: 9076480
[TBL] [Abstract][Full Text] [Related]
32. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
Grese TA; Cho S; Finley DR; Godfrey AG; Jones CD; Lugar CW; Martin MJ; Matsumoto K; Pennington LD; Winter MA; Adrian MD; Cole HW; Magee DE; Phillips DL; Rowley ER; Short LL; Glasebrook AL; Bryant HU
J Med Chem; 1997 Jan; 40(2):146-67. PubMed ID: 9003514
[TBL] [Abstract][Full Text] [Related]
33. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.
Yano T; Pinski J; Szepeshazi K; Milovanovic SR; Groot K; Schally AV
Prostate; 1992; 20(4):297-310. PubMed ID: 1351672
[TBL] [Abstract][Full Text] [Related]
34. Vitamin D receptor-dependent antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic analogues in three in vivo models of prostate cancer.
Oades GM; Dredge K; Kirby RS; Colston KW
BJU Int; 2002 Oct; 90(6):607-16. PubMed ID: 12230626
[TBL] [Abstract][Full Text] [Related]
35. Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance.
Yang NN; Bryant HU; Hardikar S; Sato M; Galvin RJ; Glasebrook AL; Termine JD
Endocrinology; 1996 May; 137(5):2075-84. PubMed ID: 8612550
[TBL] [Abstract][Full Text] [Related]
36. The rat endometrial adenocarcinoma cell line RUCA-I: a novel hormone-responsive in vivo/in vitro tumor model.
Vollmer G; Schneider MR
J Steroid Biochem Mol Biol; 1996 Apr; 58(1):103-15. PubMed ID: 8809192
[TBL] [Abstract][Full Text] [Related]
37. Effects of estradiol and raloxifene analog on brain, adrenal and serum allopregnanolone content in fertile and ovariectomized female rats.
Genazzani AR; Bernardi F; Stomati M; Monteleone P; Luisi S; Rubino S; Farzati A; Casarosa E; Luisi M; Petraglia F
Neuroendocrinology; 2000 Sep; 72(3):162-70. PubMed ID: 11025410
[TBL] [Abstract][Full Text] [Related]
38. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats.
Sato M; McClintock C; Kim J; Turner CH; Bryant HU; Magee D; Slemenda CW
J Bone Miner Res; 1994 May; 9(5):715-24. PubMed ID: 8053401
[TBL] [Abstract][Full Text] [Related]
39. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.
Getzenberg RH; Light BW; Lapco PE; Konety BR; Nangia AK; Acierno JS; Dhir R; Shurin Z; Day RS; Trump DL; Johnson CS
Urology; 1997 Dec; 50(6):999-1006. PubMed ID: 9426741
[TBL] [Abstract][Full Text] [Related]
40. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.
Gottardis MM; Jordan VC
Cancer Res; 1987 Aug; 47(15):4020-4. PubMed ID: 3607747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]